Quince Therapeutics (QNCX) Total Non-Current Liabilities (2022 - 2026)
Quince Therapeutics (QNCX) posted quarterly Total Non-Current Liabilities of $9.8 million for Q1 2026, down 67.37% year-over-year from $29.9 million in Q1 2025, and down 92.36% quarter-over-quarter from $127.7 million in Q4 2025.
Quince Therapeutics (QNCX) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Quince Therapeutics' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $9.8 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 67.37% year-over-year to $9.8 million; the TTM figure through Mar 2026 stood at $9.8 million (down 67.37% YoY), while the FY2025 annual figure was $127.7 million, up 51.39% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $9.8 million, down from $127.7 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $127.7 million in Q4 2025, with the low at $3.3 million in Q4 2022.
- The 5-year median for Total Non-Current Liabilities is $82.2 million (2023), against an average of $61.4 million.
- The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities jumped 2379.02% in 2023, then slumped 67.37% in 2026.
- Quince Therapeutics' Total Non-Current Liabilities stood at $3.3 million in 2022, then surged by 2379.02% to $82.2 million in 2023, then gained by 2.56% to $84.3 million in 2024, then jumped by 51.39% to $127.7 million in 2025, then slumped by 92.36% to $9.8 million in 2026.
- Business Quant data shows QNCX's Total Non-Current Liabilities at $9.8 million in Q1 2026, $127.7 million in Q4 2025, and $108.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | 9.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.76 Mn |
| Dec 31, 2025 | 127.67 Mn |
| Sep 30, 2025 | 108.06 Mn |
| Jun 30, 2025 | 104.73 Mn |
| Mar 31, 2025 | 29.89 Mn |
| Dec 31, 2024 | 84.33 Mn |
| Sep 30, 2024 | 26.80 Mn |
| Jun 30, 2024 | 87.25 Mn |
| Mar 31, 2024 | 11.35 Mn |
| Dec 31, 2023 | 82.23 Mn |
| Dec 31, 2022 | 3.32 Mn |